Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
JAMA. Author manuscript; available in PMC 2013 May 30.
Published in final edited form as:
PMCID: PMC3667653

Variants in the ATP-Binding Cassette Transporter (ABCA7), Apolipoprotein E ε4, and the Risk of Late-Onset Alzheimer Disease in African Americans



Genetic variants associated with susceptibility to late-onset Alzheimer disease are known for individuals of European ancestry, but whether the same or different variants account for the genetic risk of Alzheimer disease in African American individuals is unknown. Identification of disease-associated variants helps identify targets for genetic testing, prevention, and treatment.


To identify genetic loci associated with late-onset Alzheimer disease in African Americans.

Design, Setting, and Participants

The Alzheimer Disease Genetics Consortium (ADGC) assembled multiple data sets representing a total of 5896 African Americans (1968 case participants, 3928 control participants) 60 years or older that were collected between 1989 and 2011 at multiple sites. The association of Alzheimer disease with genotyped and imputed single-nucleotide polymorphisms (SNPs) was assessed in case-control and in family-based data sets. Results from individual data sets were combined to perform an inverse variance–weighted meta-analysis, first with genome-wide analyses and subsequently with gene-based tests for previously reported loci.

Main Outcomes and Measures

Presence of Alzheimer disease according to standardized criteria.


Genome-wide significance in fully adjusted models (sex, age, APOE genotype, population stratification) was observed for a SNP in ABCA7 (rs115550680, allele = G; frequency, 0.09 cases and 0.06 controls; odds ratio [OR], 1.79 [95% CI, 1.47-2.12]; P = 2.2 × 10–9), which is in linkage disequilibrium with SNPs previously associated with Alzheimer disease in Europeans (0.8<D'<0.9). The effect size for the SNP in ABCA7 was comparable with that of the APOE ε4–determining SNP rs429358 (allele = C; frequency, 0.30 cases and 0.18 controls; OR, 2.31 [95% CI, 2.19-2.42]; P = 5.5 × 10–47). Several loci previously associated with Alzheimer disease but not reaching significance in genome-wide analyses were replicated in gene-based analyses accounting for linkage disequilibrium between markers and correcting for number of tests performed per gene (CR1, BIN1, EPHA1, CD33; 0.0005<empirical P < .001).

Conclusions and Relevance

In this meta-analysis of data from African American participants, Alzheimer disease was significantly associated with variants in ABCA7 and with other genes that have been associated with Alzheimer disease in individuals of European ancestry. Replication and functional validation of this finding is needed before this information is used in clinical settings.

Late-onset Alzheimer disease (LOAD) is the most common cause of dementia, increasing in frequency from 1% at age 65 years to more than 30% for people older than 80 years.1 As much as 20% of the disease-attributable risk is related to the ε4 variant in APOE.2 A series of large genome-wide association studies (GWASs) identified several additional variants that affect disease susceptibility in non-Hispanic whites of European ancestry, including CR1, CLU, PICALM, BIN1, CD2AP, CD33, EPHA1, MS4A6A/MS4E4, and ABCA7.3-7 In addition, SORL1 was identified as a susceptibility gene in candidate gene and functional studies.8,9 However, LOAD heritability estimates are high (h2 ≈60%-80%), and a large part of the genetic contribution to LOAD remains unexplained.10

The incidence of LOAD among African Americans is higher than among whites living in the same community,11 and the reported risk for the disease associated with APOE ε4 heterozygosity is inconsistent in African Americans compared with whites.12 African Americans and other minorities are understudied, and it is unclear whether any of the recently identified loci modify risk of LOAD in racial or ethnic groups other than whites.

To identify genetic variants associated with LOAD in African Americans, the Alzheimer Disease Genetics Consortium (ADGC) performed a GWAS among the largest sample, to our knowledge, of African Americans ever assembled for genetic studies of Alzheimer disease.


Study Samples

Participants were recruited from several independent community-based case-control and family studies of African Americans collected over a period of approximately 30 years between 1989 and 2011.12-35 All participants underwent rigorous phenotyping for LOAD, and diagnoses were made by National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association criteria.36 Classification of participants as African American was based on self-report using the format of the 1990 US census.37 A detailed description of the original cohorts contributing samples is provided in the eMethods, available at A glossary of terms used in this article is provided in the Box.

All participants provided written informed consent, and the data sets for the study were approved for analysis by the relevant institutional review boards.

Censoring Age

Information on age at onset for case participants and age at examination or death for control participants was available for most cohorts. However, surrogate age information was available for other data sets including age at ascertainment (Indiana University), age at diagnosis (Chicago Health and Aging Project [CHAP], Minority Aging Research Study/Clinical Minority Core [MARS/CORE]), or age at death (subset of autopsy-confirmed samples in the University of Miami/Vanderbilt University [UM/VU] cohort). Age at death was used for autopsied participants. To restrict the analyses to case participants with LOAD, persons younger than 60 years at last evaluation, symptom onset, or death were excluded.


GWAS genotypes were from a variety of Illumina arrays (eTable 1). For all data sets, case and control samples were randomly plated to minimize potential batch effects. For the Alzheimer Disease Centers, Adult Changes in Thought, National Institute in Aging–LOAD/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD), UM/VU, CHAP, Columbia University, and Mayo Clinic cohorts, APOE genotypes were based on haplotypes derived from single-nucleotide polymorphisms (SNPs) rs7412 and rs429358. For the MIRAGE and GenerAAtions cohorts, APOE genotypes were determined using the Roche Diagnostics LightCycler 480 instrument (Roche Diagnostics)38 and LightMix Kit ApoE C112R R158 (TIB MOLBIOL); for the University of Pittsburgh, Washington Heights Columbia Aging Project, and Indianapolis cohorts, they were determined by pyrosequencing39 or analysis of restriction fragment length polymorphisms40,41; for the Religious Orders Study/Rush Memory and Aging Project (ROS/MAP) and MARS/CORE they were determined by high-throughput sequencing of codons 112 and 158 in APOE by Agencourt Bioscience Corporation; for the Washington University samples they were determined using a taqman-based assay from Applied Biosystems. Single-nucleotide polymorphisms were annotated based on the National Center for Biotechnology Information (NCBI) Reference Sequence database and the GRCh37/hg19 genome build; genes were annotated using NCBI Entrez Gene accession number.

Quality Control Procedures

Single-nucleotide polymorphisms with minor allele frequencies (MAFs) less than 0.01, call rates less than 98%, or not in Hardy-Weinberg equilibrium (P < 10–6 in controls) were excluded. Participants whose reported sex differed from the sex assignment determined by analysis of the X-chromo-some SNPs using PLINK version 1.07 ( were excluded. For cohorts genotyped on multiple chips (MIRAGE, UM/VU), quality control was performed separately for the subsets of individuals genotyped using different chips. Latent relatedness among participants within and across the case-control cohorts was identified by the estimated proportion of alleles (π) shared identical by descent (IBD) using PLINK. The proportion IBD is calculated by estimating the probability of sharing 0, 1, or 2 alleles IBD for any 2 individuals (π = P [IBD = 2] + 0.5 × P [IBD = 1], where P indicates probability). One participant from each duplicate pair (π > 0.95) or relative pair (0.4 ≤ π < 0.95) was included in the sample used for association analyses, prioritizing based on nonmissing disease status and then higher SNP call rate. Relationships among individuals in the family-based cohorts (MIRAGE, NIA-LOAD/NCRAD) were confirmed by pairwise genome-wide estimates of IBD allele sharing. All discrepancies were reviewed with clinical and pedigree data to determine the most likely relationship consistent with IBD estimates.

Population Substructure

Population substructure was evaluated in each cohort separately using EIGENSTRAT (EIGENSOFT version 3.0) ( First, genetic profiles for all participants in the case-control data sets and a group of unrelated participants in the MIRAGE family-based data set were compared with those in the HapMap reference panel of African Americans (African ancestry in the Southwest USA), and outliers with respect to African American ancestry were removed from the sample. Then, the data were reevaluated using EIGENSTRAT to derive loadings for the first 10 principal components. Principal component analysis was used to model for each assessed marker ancestry differences in frequency between case and control participants. The resulting information can be used to adjust for population substructure, which minimizes spurious associations and maximizes power to detect true associations.

Genotype Imputation

Genome-wide imputation of allele dosages was performed using the June 2011 panel from 1000 Genomes build 37 for imputation of genotypes ( and the IMPUTE2 ( software applying strict prephasing, preimputation filtering, and variant position and strand alignment control.43 The reference panel used is a multi-reference panel specifically developed for imputation of nonwhite populations and shown to impute genotypes in African Americans with high accuracy.43,44 Only imputed SNP dosages with an imputation quality estimate of R2 ≥ 0.50 were included in the final SNP set for analysis.

Association Analyses

Association of LOAD with genotyped and imputed SNPs (allele dosages) that had passed quality control was assessed using logistic regression methods for case-control data sets and logistic generalized estimating equations for family data sets as implemented in PLINK. All analyses were performed using an additive genetic model (ie, genotyped SNPs were coded 0, 1, or 2 based on the number of minor alleles [with 0 being homozygous for the reference allele, 1 being heterozygous, and 2 being homozygous for the minor allele], and imputed SNPs were coded based on the posterior probability of the minor allele [0–2]). The primary association analyses were adjusted for age, sex, and population substructure (using for each cohort the appropriate number of principal components) (Table 1).

Table 1
Characteristics of Data Sets12-35

Results from the individual data sets were combined using an inverse variance–weighted meta-analysis approach implemented in METAL ( The meta-analysis P value was estimated by the summarized test statistic after applying a genomic control within each individual study. Heterogeneity of effect estimates across data sets (I2) was tested with the χ2 distributed Q statistic.45,46 All analyses were repeated adjusting for the number of APOE-ε4 alleles (0, 1, or 2). The threshold for genome-wide significance was calculated as P ≤ 5 × 10–8, taking linkage disequilibrium between markers into account. The genomic inflation factors (λ) for each model are estimated based on the concept that apart from a small number of SNPs showing a true association with the disease, the test statistics for other SNPs should follow the distribution under the null hypothesis of no association and thus reflect cryptic population stratification, relatedness, or genotyping errors. These factors were between 0.87 and 1.03, indicating that there was no substantial inflation of the test statistics in either meta-analysis (eFigure 1). All findings with P ≤ 10–6 in the fully adjusted model were compared with results obtained in whites.5

Because of the a priori hypothesis of an involvement with LOAD, associations of SNPs in previously reported LOAD genes (CR1 [NCBI Entrez Gene 1378], BIN1 [NCBI Entrez Gene 274], PICALM [NCBI Entrez Gene 8301], CLU [NCBI Entrez Gene 1191], EPHA1 [NCBI Entrez Gene 2041], MS4A6A cluster [NCBI Entrez Gene 64231], CD2AP [NCBI Entrez Gene 23607], and CD33 [NCBI Entrez Gene 945]), were analyzed with a versatile gene-based association study (VEGAS47), adding 50 kilobases (kb) to each side. Gene-based tests for association are a useful complement to GWASs, because gene-based tests consider association between a trait and all SNPs within a gene rather than each marker individually. Depending on the underlying genetic architecture, gene-based approaches can be more powerful than traditional single-SNP–based GWASs, in particular if a gene contains several SNPs with marginal levels of significance that are often indistinguishable from random noise in the initial GWAS. For the specific gene assessed, VEGAS incorporates linkage disequilibrium information from a set of reference individuals from HapMap, determines the number of tagging SNPs, and calculates the empirical P value for the gene by using simulations from the multivariate normal distribution.47 Accordingly, the P value threshold for significance differs between genes depending on the linkage disequilibrium structure and number of tagging SNPs assessed.

Strength of linkage disequilibrium—which is a measure of the association of 2 alleles at different loci—between different SNPs observed in the same gene in this African American sample and the white samples was determined by estimating D’. D’ ranges from 0 to 1, with 0 indicating no linkage (ie, fully independent transmission from parent to offspring) and 1 indicating perfect linkage (ie, completely linked transmission from parent to offspring) between 2 markers. In contrast to R2, D’ is not influenced by differences in allele frequencies between ethnic groups.


We performed the GWAS using data from 1968 African American case participants with LOAD and 3928 cognitively normal elderly control participants. Fifty percent of the cohort had preexisting genome-wide genotyping, and another 1074 cases and 1908 controls were genotyped specifically for this project. Several characteristics of the individual data sets are shown in Table 1.

The final SNP set included a total of 17 332 474 genotyped and imputed variants. The association with the lowest P value was with APOE (NCBI Entrez Gene 348). In models adjusting for age, sex, and population stratification, numerous SNPs in the APOE region were significant (eg, rs429358, P = 5.5 × 10–47) for association with LOAD. Excluding SNPs in the APOE region, the strongest associations were observed for rs10247412 in ELMO1 (NCBI Entrez Gene 9844) (odds ratio [OR], 0.66 [95% CI, 0.56-0.77]; P = 2.9 × 10–7), rs885330 in SOX13 (NCBI Entrez Gene 9580) (OR, 1.25 [95% CI, 1.17-1.33]; P = 3.9 × 10–7), an intergenic SNP (rs145848414) at 174 014 114 base pairs on chromosome 5q35.2 that is not near any genes with a known function (OR, 2.03 [95% CI, 1.54-2.67]; P = 5.1 × 10–7), and rs115550680 in ABCA7 (NCBI Entrez Gene 10347) (OR, 1.78 [95% CI, 1.28-1.82]; P = 1.4 × 10–6). After adjustment for APOE, the associations with ELMO1 and SOX13 SNPs diminished, whereas the association for rs115550680 in ABCA7 (OR, 1.79 [95% CI, 1.47-2.12]; P = 2.21 × 10–9) became stronger (Table 2). The association of rs145848414 on chromosome 5q35.2 with LOAD also became stronger but did not fully reach genome-wide significance (OR, 2.29 [95% CI, 1.69-3.09]; P = 6.9 × 10–8). The increases in effect size were accompanied by decreases in P value, which were most pronounced in the larger data sets (ADGC, CHAP, MIRAGE660, Indianapolis).

Table 2
Genome-Wide Meta-analysis Results of Fully Adjusted Model for Single-Nucleotide Polymorphisms with P ≤ 10–8 Excluding the APOE Regiona,b

In African Americans, the SNP in ABCA7 (rs115550680) is in linkage disquilibrium with 2 other ABCA7 SNPs previously associated with LOAD at the genome-wide significance level in non-Hispanic whites of European ancestry (rs3764650 [Hollingworth et al3] and rs3752246 [Naj et al5], 0.8<D’ = 0.9) (Figure 1) and showed the same direction of effect. The effect size for rs115550680 in ABCA7 (OR, 1.79 [95% CI, 1.47-2.12]; P = 2.21 × 10–9) was comparable with that observed for APOE (OR, 2.31 [95% CI, 2.19-2.42]; P = 5.5 × 10–47). Comparison of regional association plots for ABCA7 in this African American sample and the non-Hispanic white sample described in Naj et al5 showed more widespread associations among African Americans (Figure 2). Consistent with this finding, in this African American sample, SNPs at 2 adjacent loci on chromosome 19p (GRIN3B [NCBI Entrez Gene 116444] and HMHA1 [NCBI Entrez Gene 23526]) were associated with LOAD at P ≤ 10–8 in the fully adjusted model (Table 2). ABCA7, GRIN3B, and HMHA1 span a 81-kb region on chromosome 19p and are in linkage dis-equilibrium (0.8<D'<0.95) (Table 2). Further analyses conditioned on rs115550680 in ABCA7 revealed that the associations in GRIN3B and HMHA1 were not independent (eTable 2)

Figure 1
Linkage Disequilibrium Pattern of Single-Nucleotide Polymorphisms in ABCA7 Based on the HapMap Reference Sample (African Americans in the Southwest USA) and NCBI36/hg18 Genome Build
Figure 2
Regional Association Plot of the ABCA7 Region (±100 Kilobases) in the African American Sample and the White Sample Described in Naj et al5 Based on the GRCh37/hg19 Genome Build

The imputation quality (R^2) for rs115550680 in ABCA7, the significant SNPs in GRIN3B, HMHA1, and the novel locus on chromosome 5q35.2 was high (0.87-0.99) across all data sets included in the analyses (eTable 3). Forest plots (eFigure 2) indicated the consistency of results across data sets. The ABCA7 SNPs previously reported in whites (rs37646503 and rs37522465) did not reach genome-wide significance in this African American data set. However, the MAFs for these 2 vari ants largely differ between populations of European and African descent (MAF for rs3764650, 0.25 in African Americans and 0.11 in Europeans; MAF for rs3752246, 0.04 in African Americans and 0.19 in Europeans). In turn, rs115550680, significant in this African American data set, is monomorphic in Europeans. However, as described above, the direction of effects of rs115550680, rs3764650, and rs3752246 were similar.

The susceptibility loci previously associated with LOAD in whites, which did not reach the P value cutoff for genome-wide significance in this African American data set (CR1, BIN1, PICALM, CLU, EPHA1, MS4A cluster, CD2AP, CD33), were further explored in gene-based analyses adding 50 kb to both sides of each gene.3-7Table 3 shows the genes significant in these gene-based tests and reports information on the number of tagging SNPs assessed in each gene and the corresponding P value threshold needed to reach statistical significance. After correcting for the number of independent tests per gene, SNPs in CR1 (rs146366639: OR, 0.82 [95% CI, 0.73-0.92]; empirical P = .0005), BIN1 (rs55636820: OR, 1.89 [95% CI, 1.31-2.75]; empirical P = .0007), EPHA1 (rs6973770: OR, 0.70 [95% CI, 0.56-0.87]; empirical P = .001), and CD33 (rs114282264: OR, 0.61 [95% CI, 0.47-0.81]; empirical P = .0007) were significantly associated with LOAD, although the most significant SNPs differed from the top-ranked SNPs in Europeans.

Table 3
Known Genetic Loci Associated With Alzheimer Disease in the African American Data Set in a Versatile Gene-Based Association Study (VEGAS47)a


To our knowledge, the present study is the largest GWAS for the study of LOAD in African Americans ever assembled. Aside from SNPs associated with APOE, the top-ranked SNP observed in this study was located in ABCA7 (rs115550680) and had an effect size comparable with that of APOE ε4. This observation differs from the previous GWAS in whites. The reported ABCA7 SNPs in non-Hispanic whites have lower effect sizes (rs3752246: OR, 1.13 [95% CI, 1.03-1.25]; rs3764650: OR, 1.23 [95% CI, 1.17-1.28]),3,5 as do all other genes reported in whites (CR1, BIN1, PICALM, CLU, EPHA1, MS4A cluster, CD2AP, CD33).3-6

It remains possible that this could be attributable to population differences in the frequencies of the causative variant(s) tagged by the associated SNPs (rs115550680 in ABCA7 is monomorphic in non-Hispanic whites; the MAF for rs3752246 is 0.04 in African Americans and 0.19 in non-Hispanic whites; the MAF for rs3764650 is 0.25 in African Americans and 0.11 in non-Hispanic whites) or the result of a bias in the estimated effect of a newly identified allele on disease (also termed “winner's curse”).

However, it is also possible that the large difference between whites and African Americans in the effect size of the ABCA7 locus on the relative odds of being diagnosed with LOAD is explained by population-specific causative variants with variable influence on protein structure or function. The linkage disequilibrium block in which rs115550680 is located spans across several introns and exons (Figure 1), implying that rs115550680 is in dis-equilibrium with exonic variants that could be potentially causative. Thus, although the findings of this study require replication in an independent African American sample with enough power to detect small ORs as well as functional confirmation, support for our findings comes from the previous studies in whites observing ABCA7 as a risk locus in Alzheimer disease, albeit with marginal effects.3,5

If validated by future replication and functional studies, identification of ABCA7 as a risk gene in LOAD among African Americans not only may help elucidate the disease etiology but also may have major implications for developing targets for genetic testing, prevention, and treatment. ABCA7 is an integral transmembrane adenosine triphosphate–binding cassette transporter that belongs to the ABC family proteins and that mediates the biogenesis of high-density lipoprotein with cellular lipid and helical apolipoproteins.48 It binds apolipoprotein A1 and functions in apolipoprotein-mediated phospholipid and cholesterol efflux from cells.49

The findings of the current study suggest that lipid metabolism is a prominent pathway of LOAD in African Americans. This is consistent with the fact that cardiovascular and cerebrovascular diseases are more prominent in African Americans than in non-Hispanic whites.50 Moreover, dyslipidemia and cardiovascular and cerebrovascular diseases are well-recognized risk factors for LOAD,51,52 and the LOAD-related genes SORL1, CLU, and APOE are also involved in lipid metabolism. If confirmed, focusing on the role of lipid metabolism in LOAD may have significant effects on disease management.

ABCA7 also affects the transport of other important proteins, including amyloid precursor protein,49 through the cell membrane and is involved in host defense through effects on phagocytosis by macrophages of apoptotic cells.48 Thus, there are multiple ways in which ABCA7 might affect risk of LOAD.

Compared with the findings described in Naj et al5 among non-Hispanic whites, the area including significant SNP associations in the ABCA7 region was broader in the African American sample. It is possible that this broad region of association in African Americans is attributable to a large, ancestral risk haplotype recently introduced by admixture with white (“European”) Americans and has remained substantially intact within African Americans because of the relatively short time since its introduction. In contrast, the risk allele may exist on several different haplotypes in non-Hispanic whites (ie, may be older), only a subset of which was introduced into the African American population.

In a previous study,5 the ADGC reported genome-wide associations for variants in MSA4, CD2AP, CD33, and EPHA1 among individuals of white European ancestry. A cohort-based consortium comprising whites from the United Kingdom, Europe, and the United States had similar findings and first reported the association between SNPs in ABCA7 and Alzheimer disease.3 Logue et al29 reported nominal significance for the ABCA7 SNP rs3764650 reported by Hollingworth et al3 in a well-characterized cohort of 513 African American persons with Alzheimer disease and 496 cognitively normal controls. As described above, the effect sizes for the association between ABCA7 and LOAD in these studies is small compared with the effect size observed in the current study. In the current study CR1, BIN1, EPHA1, and CD33 were replicated with significance in gene-based analyses. Differences in disease-associated SNPs in these loci between the white and African American consortium data sets also reflect differences in degree of variation and size of haplotype blocks, which in turn is helpful in identifying the true causative variants.

This study has limitations. Because of the paucity of available African American data sets for LOAD, we could not divide the assembled data sets into discovery and replication data sets but rather used the ADGC white race data set for replication. Thus, this study requires replication in an independent African American sample. In addition, we had limited power to detect associations with small effect sizes and associations with rare variants. Although all data sets included in the analytic sample used accepted clinical or pathological criteria to define LOAD, phenotypic heterogeneity between samples may have limited our ability to detect some associations.

In addition, the top-ranked SNP observed in ABCA7 was not directly genotyped but imputed in all data sets. However, several facts make it unlikely that the observed association was caused by imputation error. First, as stated above and shown in Figure 1, rs115550680 is in linkage disequilibrium with the 2 ABCA7 SNPs reported by Naj et al5 and Hollingworth et al3 in non-Hispanic whites of European ancestry (rs3764650 and rs3752246, 0.8<D’ = 0.9) that make this finding plausible. Second, the imputation quality (R^2) of this SNP is high across all data sets (0.89<R^2<0.99) (eTable 3). Third, the MAF of rs115550680 in our African American sample is 7%. Although in general the imputation error rate increases with decreasing MAF, several recent studies suggest that SNPs with MAFs less than 5% are especially prone to imputation errors.36 The recent study by Hancock et al,53 which specifically assessed genotype imputation performance using 1000 Genomes reference panels in African Americans, determined that the threshold for high imputation lies at MAF 2% or greater, applying the software and reference panel used in the present study.

The variant associations reported herein reflect a portion of the genetic influences of common alleles on LOAD in African Americans. Among these, ABCA7 and APOE genotype were the strongest risk factors that both substantially increased the risk of LOAD (OR, 1.79 and 2.31, respectively). Identification of the genetic risk variants by resequencing and validation by functional studies would allow refinement of risk estimates and diagnostic and predictive testing protocols specific for African Americans.

Box. Glossary of Terms

Genome-wide analysis: A genetic study evaluating the potential linkage of genetic markers located throughout the genome to a specific trait. This approach has been used for mendelian (single-gene) disorders as well as complex traits (genome-wide association study).

Haplotype: The combination of linked marker alleles (may be polymorphisms or mutations) for a given region of DNA on a single chromosome.

Imputation: A statistical method for inferring genotypes that are not directly measured.

Linkage disequilibrium: Refers to alleles at loci close enough together that they remain inherited together through many generations because their extreme close proximity makes recombination (crossing over) between them highly unlikely.

For a complete list of genomic terms, see the Appendix in this issue.

Supplementary Material

Supplementary Data


Funding/Support: The NIA supported this work through grants U01-AG032984, RC2-AG036528, U01-AG016976 (Dr Kukull); U24 AG026395, U24 AG026390, R01AG037212, R37 AG015473 (Dr Mayeux); K23AG034550 (Dr Reitz); U24-AG021886 (Dr Foroud); R01AG009956, RC2 AG036650 (Dr Hall); UO1 AG06781, UO1 HG004610 (Dr Larson); R01 AG009029 (Dr Farrer); 5R01AG20688 (Dr Fallin); P50 AG005133, AG030653 (Dr Kamboh); R01 AG019085 (Dr Haines); R01 AG1101, R01 AG030146, RC2 AG036650 (Dr Evans); P30AG10161, R01AG15819, R01AG30146, R01AG17917, R01AG15819 (Dr Bennett); R01AG028786 (Dr Manly); R01AG22018, P30AG10161 (Dr Barnes); P50AG16574 (Dr Ertekin-Taner, Dr Graff-Radford), R01 AG032990 (Dr Ertekin-Taner), KL2 RR024151 (Dr Ertekin-Taner); R01 AG027944, R01 AG028786 (Dr Pericak-Vance); P20 MD000546, R01 AG28786-01A1 (Dr Byrd); AG005138 (Dr Buxbaum); P50 AG05681, P01 AG03991, P01 AG026276 (Dr Goate); and P30AG019610, P30AG13846, U01-AG10483, R01CA129769, R01MH080295, R01AG017173, R01AG025259, R01AG33193, P50AG008702, P30AG028377, AG05128, AG025688, P30AG10133, P50AG005146, P50AG005134, P01AG002219, P30AG08051, MO1RR00096, UL1RR029893, P30AG013854, P30AG008017, R01AG026916, R01AG019085, P50AG016582, UL1RR02777, R01AG031581, P30AG010129, P50AG016573, P50AG016575, P50AG016576, P50AG016577, P50AG016570, P50AG005131, P50AG023501, P50AG019724, P30AG028383, P50AG008671, P30AG010124, P50AG005142, P30AG012300, AG010491, AG027944, AG021547, AG019757, P50AG005136 (Alzheimer Disease GeneticsConsortium [ADGC]). We thank Creighton Phelps, Stephen Synder, and Marilyn Miller from the NIA, who are ex-officio members of the ADGC. Support was also provided by the Alzheimer's Association (IIRG-08-89720 [Dr Farrer] and IIRG-05-14147 [Dr Pericak-Vance]), National Institute of Neurological Disorders and Stroke grant NS39764, National Institute of Mental Health grant MH60451, GlaxoSmithKline, and the Office of Research and Development, Biomedical Laboratory Research Program, US Department of Veterans Affairs Administration. For the ADGC, biological samples and associated phenotypic data used in primary data analyses were stored at principal investigators’ institutions and at the National Cell Repository for Alzheimer's Disease (NCRAD) at Indiana University, funded by the NIA. Associated phenotypic data used in secondary data analyses were stored at the National Alzheimer's Coordinating Center and at the NIA Alzheimer's Disease Data Storage Site at the University of Pennsylvania, funded by the NIA. Contributors to the genetic analysis data included principal investigators on projects ndividually funded by the NIA, other NIH institutes, or private entities.

Role of the Sponsor: The funding organizations and sponsors had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.


Author Contributions: Dr Mayeux had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Reitz, Buxbaum, Fallin, Griffith, Obisesan, Manly, Bennett, Haines, Farrer, Pericak-Vance, Schellenberg, Mayeux.

Acquisition of data: Reitz, Valladares, Lin, Larson, Graff-Radford, Evans, Crane, Buxbaum, Murrell, Ertekin-Taner, Baldwin, Green, Barnes, Cantwell, Fallin, Go, Obisesan, Manly, Kamboh, Lopez, Bennett, Hendrie, Hall, Goate, Byrd, Kukull, Foroud, Haines, Farrer, Pericak-Vance, Schellenberg, Mayeux.

Analysis and interpretation of data: Reitz, Jun, Naj, Rajbhandary, Vardarajan, Wang, Valladares, Graff-Radford, De Jager, Crane, Buxbaum, Raj, Ertekin-Taner, Logue, Manly, Lunetta, Bennett, Hendrie, Farrer, Pericak-Vance, Schellenberg, Mayeux.

Drafting of the manuscript: Reitz, Naj, De Jager, Raj, Cantwell, Pericak-Vance, Mayeux.

Critical revision of the manuscript for important intellectual content: Reitz, Jun, Naj, Rajbhandary, Vardarajan, Wang, Valladares, Lin, Larson, Graff-Radford, Evans, Crane, Buxbaum, Murrell, Ertekin-Taner, Logue, Baldwin, Green, Barnes, Fallin, Go, Griffith, Obisesan, Manly, Lunetta, Kamboh, Lopez, Bennett, Hendrie, Hall, Goate, Byrd, Kukull, Foroud, Haines, Farrer, Pericak-Vance, Schellenberg, Mayeux.

Statistical analysis: Reitz, Jun, Naj, Rajbhandary, Vardarajan, Raj, Logue, Hall, Lunetta, Hendrie, Haines, Farrer, Pericak-Vance.

Obtained funding: Larson, Evans, Murrell, Green, Barnes, Fallin, Go, Manly, Kamboh, Bennett, Goate, Byrd, Haines, Pericak-Vance, Schellenberg, Mayeux.

Administrative, technical, or material support: Naj, Wang, Valladares, Lin, Larson, Crane, Buxbaum, Murrell, Ertekin-Taner, Baldwin, Green, Cantwell, Fallin, Obisesan, Kamboh, Lopez, Bennett, Hall, Goate, Byrd, Kukull, Foroud, Farrer, Schellenberg, Mayeux.

Study supervision: Go, Obisesan, Bennett, Hendrie, Byrd, Foroud, Farrer, Schellenberg, Mayeux.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Baldwin reported serving as a consultant for the Center for Human Genetics Inc. Dr Go reported receiving travel support from the National Institutes of Health (NIH). Dr Griffith reported receiving payment for lectures from Eisai and Pfizer. Dr Manly reported serving as a board member for the International Neuropsychological Society; receiving grants or grants pending from the Alzheimer's Association and the National Institute on Aging (NIA); and receiving travel expenses from the Alzheimer's Association. Dr Kamboh reported receiving travel support from the NIH. Dr Lopez reported receiving consulting fees or honoraria from Mertz and Lundbeck. Dr Bennett reported receiving travel support from the NIH. Dr Goate reported serving as a consultant for Finnegan; providing expert testimony in cases involving the genetics of Alzheimer disease; receiving grants or grants pending from Genentech and Pfizer; receiving payment for lectures from Pfizer, Genentech, and Amgen; and receiving patent royalties from Taconic for a tau mutation. Dr Pericak-Vance reported receiving revenues from Athena Diagnostics. No other authors reported disclosures.

Members of the Alzheimer's Disease Genetics Consortium: Marilyn S. Albert, Roger L. Albin, Liana G. Apostolova, Steven E. Arnold, Robert Barber, Michael M. Barmada, Thomas G. Beach, Gary W. Beecham, Duane Beekly, Eileen H. Bigio, Thomas D. Bird, Deborah Blacker, Bradley F. Boeve, James D. Bowen, Adam Boxer, James R. Burke, Guiqing Cai, Nigel J. Cairns, Chuanhai Cao, Chris S. Carlson, Regina M. Carney, Steven L. Carroll, Helena C. Chui, David G. Clark, David H. Cribbs, Elizabeth A. Crocco, Carlos Cruchaga, Charles DeCarli, Steven T. DeKosky, F. Yesim Demirci, Malcolm Dick, Kelley M. Faber, Kenneth B. Fallon, Martin R. Farlow, Steven Ferris, Matthew P. Frosch, Douglas R. Galasko, Mary Ganguli, Marla Gearing, Daniel H. Geschwind, Bernardino Ghetti, John R. Gilbert, Sid Gilman, Jonathan D. Glass, John H. Growdon, Hakon Hakonarson, Ronald L. Hamilton, Kara L. Hamilton-Nelson, Vahram Haroutunian, Lindy E. Harrell, Elizabeth Head, Lawrence S. Honig, Christine M. Hulette, Bradley T. Hyman, Gail P. Jarvik, Gregory A. Jicha, Lee-Way Jin, Anna Karydas, John S. K. Kauwe, Jeffrey A. Kaye, Ronald Kim, Edward H. Koo, Neil W. Kowall, Joel H. Kramer, Patricia Kramer, Frank M. LaFerla, James J. Lah, Rosalyn Lang-Walker, James B. Leverenz, Allan I. Levey, Ge Li, Andrew P. Lieberman, Constantine G. Lyketsos, Wendy J. Mack, Daniel C. Marson, Eden R. Martin, Frank Martiniuk, Deborah C. Mash, Eliezer Masliah, Wayne C. McCormick, Susan M. McCurry, Andrew N. McDavid, Ann C. McKee, Marsel Mesulam, Bruce L. Miller, Carol A. Miller, Joshua W. Miller, Thomas J. Montine, John C. Morris, John M. Olichney, Joseph E. Parisi, Elaine Peskind, Ronald C. Petersen, Aimee Pierce, Wayne W. Poon, Huntington Potter, Joseph F. Quinn, Ashok Raj, Murray Raskind, Eric M. Reiman, Barry Reisberg, John M. Ringman, Erik D. Roberson, Howard J. Rosen, Roger N. Rosenberg, Mary Sano, Andrew J. Saykin, Julie A. Schneider, Lon S. Schneider, William W. Seeley, Amanda G. Smith, Joshua A. Sonnen, Salvatore Spina, Robert A. Stern, Rudolph E. Tanzi, John Q. Trojanowski, Juan C. Troncoso, Debby W. Tsuang, Vivi-anna M. Van Deerlin, Linda J. Van Eldik, Harry V. Vinters, Jean Paul Vonsattel, Sandra Weintraub, Kathleen A. Welsh-Bohmer, Jennifer Williamson, Randall L. Woltjer, Clinton B. Wright, Steven G. Younkin, Chang-En Yu, and Lei Yu.

Online-Only Material: eTables 1-3, eFigures 1 and 2, eMethods, and Author Video Interview are available at


1. Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15(5):365–375. [PubMed]
2. Slooter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998;55(7):964–968. [PubMed]
3. Hollingworth P, Harold D, Sims R, et al. Alzheimer's Disease Neuroimaging Initiative. CHARGE Consortium. EADI1 Consortium Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429–435. [PMC free article] [PubMed]
4. Lambert JC, Heath S, Even G, et al. European Alzheimer's Disease Initiative Investigators Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094–1099. [PubMed]
5. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436–441. [PMC free article] [PubMed]
6. Seshadri S, Fitzpatrick AL, Ikram MA, et al. CHARGE Consortium. GERAD1 Consortium. EADI1 Consortium Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832–1840. [PMC free article] [PubMed]
7. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41(10):1088–1093. [PMC free article] [PubMed]
8. Reitz C, Cheng R, Rogaeva E, et al. Genetic and Environmental Risk in Alzheimer Disease 1 Consortium Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol. 2011;68(1):99–106. [PMC free article] [PubMed]
9. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168–177. [PMC free article] [PubMed]
10. Gatz M, Pedersen NL, Berg S, et al. Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci. 1997;52(2):M117–M125. [PubMed]
11. Tang MX, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56(1):49–56. [PubMed]
12. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279(10):751–755. [PubMed]
13. Barnes LL, Shah RC, Aggarwal NT, Bennett DA, Schneider JA. The Minority Aging Research Study: ongoing efforts to obtain brain donation in African Americans without dementia. Curr Alzheimer Res. 2012;9(6):734–745. [PMC free article] [PubMed]
14. Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009;84(1):35–43. [PubMed]
15. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64(5):834–841. [PubMed]
16. Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005;25(4):163–175. [PubMed]
17. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198–205. [PubMed]
18. Berg L, McKeel DW, Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55(3):326–335. [PubMed]
19. Bienias JL, Beckett LA, Bennett DA, Wilson RS, Evans DA. Design of the Chicago Health and Aging Project (CHAP). J Alzheimers Dis. 2003;5(5):349–355. [PubMed]
20. Carrasquillo MM, Zou F, Pankratz VS, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet. 2009;41(2):192–198. [PMC free article] [PubMed]
21. Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74(2):97–109. [PMC free article] [PubMed]
22. Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 2003;60(2):185–189. [PubMed]
23. Green RC, Cupples LA, Go R, et al. MIRAGE Study Group Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287(3):329–336. [PubMed]
24. Haroutunian V, Perl DP, Purohit DP, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol. 1998;55(9):1185–1191. [PubMed]
25. Jun G, Naj AC, Beecham GW, et al. Alzheimer's Disease Genetics Consortium Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67(12):1473–1484. [PMC free article] [PubMed]
26. Kamboh MI, Minster RL, Demirci FY, et al. Association of CLU and PICALM variants with Alzheimer's disease. Neurobiol Aging. 2012;33(3):518–521. [PMC free article] [PubMed]
27. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59(11):1737–1746. [PubMed]
28. Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R, National Institute on Aging Late-Onset Alzheimer's Disease Family Study Group Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci. Arch Neurol. 2008;65(11):1518–1526. [PMC free article] [PubMed]
29. Logue MW, Schu M, Vardarajan BN, et al. Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol. 2011;68(12):1569–1579. [PMC free article] [PubMed]
30. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122–131. [PMC free article] [PubMed]
31. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord. 2006;20(4):210–216. [PubMed]
32. Murrell JR, Price B, Lane KA, et al. Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch Neurol. 2006;63(3):431–434. [PMC free article] [PubMed]
33. Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001;286(18):2239–2244. [PubMed]
34. Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67(3):467–473. [PubMed]
35. Meier IB, Manly JJ, Provenzano FA, et al. White matter predictors of cognitive functioning in older adults. J Int Neuropsychol Soc. 2012;18(3):414–427. [PMC free article] [PubMed]
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944. [PubMed]
37. US Census Bureau . 1990 Census of Population and Housing Summary File 1. US Census Bureau; Washington, DC: 1991.
38. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques. 1997;22(1):176–181. [PubMed]
39. Ahmadian A, Gharizadeh B, Gustafsson AC, et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Biochem. 2000;280(1):103–110. [PubMed]
40. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545–548. [PubMed]
41. Lai E, Riley J, Purvis I, Roses A. A 4-mb high-density single nucleotide polymorphism−based map around human APOE. Genomics. 1998;54(1):31–38. [PubMed]
42. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904–909. [PubMed]
43. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012;44(8):955–959. [PubMed]
44. Chanda P, Yuhki N, Li M, et al. Comprehensive evaluation of imputation performance in African Americans. J Hum Genet. 2012;57(7):411–421. [PMC free article] [PubMed]
45. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. [PubMed]
46. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. [PMC free article] [PubMed]
47. Liu JZ, McRae AF, Nyholt DR, et al. AMFS Investigators A versatile gene-based test for genome- wide association studies. Am J Hum Genet. 2010;87(1):139–145. [PubMed]
48. Tanaka N, Abe-Dohmae S, Iwamoto N, Yokoyama S. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J Atheroscler Thromb. 2011;18(4):274–281. [PubMed]
49. Chan SL, Kim WS, Kwok JB, et al. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem. 2008;106(2):793–804. [PubMed]
50. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–e220. [PubMed]
51. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging. 2000;21(2):153–160. [PubMed]
52. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease, I: review of epidemiological and preclinical studies. Arch Neurol. 2011;68(10):1239–1244. [PMC free article] [PubMed]
53. Hancock DB, Levy JL, Gaddis NC, et al. Assessment of genotype imputation performance using 1000 Genomes in African American studies. PLoS One. 2012;7(11):e50610. [PMC free article] [PubMed]